Enlivex Therapeutics Ltd (TA:ENLV) — Stock Price
Enlivex Therapeutics Ltd (TA:ENLV) is currently trading at ILA2.08 ILA, down 55.56% today. Over the past 52 weeks, shares have ranged between ILA0.57 and ILA614.90. This page tracks Enlivex Therapeutics Ltd's live share price on the TA exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Enlivex Therapeutics Ltd market cap and net worth.
Enlivex Therapeutics Ltd (ENLV) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Enlivex Therapeutics Ltd's daily closing share price and trading volume on the TA exchange over the past year, giving a clear view of recent price momentum and liquidity.
Enlivex Therapeutics Ltd Income Statement — Revenue, Profit & Earnings by Year
Enlivex Therapeutics Ltd's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ILA0.00 | ILA0.00 | ILA0.00 | ILA0.00 | ILA0.00 |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Research & Development | ILA10.62 Million | ILA19.23 Million | ILA18.69 Million | ILA12.88 Million | ILA6.09 Million |
| SG&A | ILA4.91 Million | ILA6.14 Million | ILA6.70 Million | ILA6.24 Million | ILA3.60 Million |
| Total Operating Expenses | ILA15.89 Million | ILA30.63 Million | ILA25.80 Million | ILA19.29 Million | ILA9.79 Million |
| Operating Income | ILA-15.89 Million | ILA-25.15 Million | ILA-25.80 Million | ILA-19.29 Million | ILA-9.79 Million |
| EBITDA | ILA-14.99 Million | ILA-24.32 Million | ILA-18.94 Million | ILA-23.77 Million | ILA-7.24 Million |
| EBIT | ILA-15.54 Million | ILA-25.15 Million | ILA-19.71 Million | ILA-24.32 Million | ILA-7.53 Million |
| Interest Expense | — | — | — | ILA0.00 | ILA0.00 |
| Income Before Tax | ILA-15.01 Million | ILA-29.07 Million | ILA-31.06 Million | ILA-14.47 Million | ILA-11.82 Million |
| Income Tax Expense | — | — | — | — | — |
| Net Income | ILA-15.01 Million | ILA-29.07 Million | ILA-31.06 Million | ILA-14.47 Million | ILA-11.82 Million |
Enlivex Therapeutics Ltd Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Enlivex Therapeutics Ltd's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ILA27.69 Million | ILA36.83 Million | ILA67.64 Million | ILA95.15 Million | ILA40.36 Million |
| Total Current Assets | ILA25.99 Million | ILA33.76 Million | ILA52.33 Million | ILA86.44 Million | ILA38.12 Million |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ILA20.20 Million | ILA26.51 Million | ILA299.00K | ILA72.93 Million | ILA30.03 Million |
| Net Receivables | ILA1.42 Million | ILA229.00K | ILA647.00K | ILA2.20 Million | ILA1.24 Million |
| Inventory | — | — | ILA3.56 Million | ILA110.69K | ILA1.25 Million |
| Property, Plant & Equipment | — | — | ILA14.90 Million | ILA2.53 Million | ILA2.14 Million |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ILA4.10 Million | ILA6.75 Million | ILA10.80 Million | ILA10.11 Million | ILA4.87 Million |
| Total Current Liabilities | ILA3.80 Million | ILA6.06 Million | ILA6.61 Million | ILA4.72 Million | ILA4.37 Million |
| Long-term Debt | — | — | — | — | — |
| Net Debt | ILA-2.77 Million | ILA219.00K | ILA-47.17 Million | ILA-5.20 Million | ILA-5.47 Million |
| Total Stockholder Equity | ILA23.59 Million | ILA30.08 Million | ILA56.84 Million | ILA85.04 Million | ILA35.49 Million |
| Retained Earnings | ILA-127.11 Million | ILA-112.09 Million | ILA-83.03 Million | ILA-51.97 Million | ILA-37.50 Million |
Enlivex Therapeutics Ltd Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Enlivex Therapeutics Ltd generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ILA-13.01 Million | ILA-23.52 Million | ILA-23.95 Million | ILA-17.54 Million | ILA-11.01 Million |
| Capital Expenditures | ILA103.00K | ILA236.00K | ILA8.12 Million | ILA1.62 Million | ILA1.02 Million |
| Free Cash Flow | ILA-13.11 Million | ILA-23.76 Million | ILA-32.08 Million | ILA-19.17 Million | ILA-12.03 Million |
| Investing Cash Flow | ILA9.06 Million | ILA-25.97 Million | ILA62.52 Million | ILA-38.41 Million | ILA-20.98 Million |
| Financing Cash Flow | ILA6.45 Million | ILA360.00K | ILA150.00K | ILA60.98 Million | ILA33.08 Million |
| Dividends Paid | — | — | — | — | — |
| Stock-Based Compensation | ILA2.06 Million | ILA1.95 Million | ILA2.71 Million | ILA2.91 Million | ILA670.00K |
| Depreciation | ILA545.00K | ILA835.00K | ILA777.00K | ILA546.00K | ILA286.00K |
| Change in Cash | ILA2.50 Million | ILA-49.13 Million | ILA38.72 Million | ILA4.62 Million | ILA1.49 Million |
Enlivex Therapeutics Ltd Earnings History — EPS Actual vs. Analyst Estimates
Track Enlivex Therapeutics Ltd's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Dec 02, 2022 | -0.31 | -0.29 | -6.90% |
| Aug 22, 2022 | -0.54 | -0.45 | -20.00% |
| May 27, 2022 | -0.45 | -0.41 | -9.76% |
| Nov 22, 2021 | -0.19 | -0.21 | +9.52% |
| Aug 06, 2021 | -0.17 | -0.26 | +34.62% |
| May 28, 2021 | -0.19 | -0.21 | +9.52% |
| Oct 30, 2020 | -0.16 | -0.18 | +11.11% |
| Aug 14, 2020 | -0.23 | -0.24 | +4.17% |